RENOVÓ
About
RENOVÓ was not built in a boardroom. It was built through a medical crisis, years of independent research, and an uncompromising refusal to accept that conventional medicine had the only answers.
What Conventional Medicine
Actually Did
The year of antibiotics and steroids did not resolve the infection. What it did was destroy everything else. His gut lining was compromised. His microbiome was in ruins. He developed allergies to gluten and dairy that he had never had before. Foods he had eaten his entire life became inflammatory triggers. Products he put on his skin caused flare-ups. His entire internal environment had been destabilised by the very treatment meant to help him.
The infection persisted. The inflammation continued. The doctors continued prescribing variations of the same approach. Nothing worked. The problem was still there — it had just become harder to manage on top of a body that was now fighting on multiple fronts simultaneously.
It was only when Dimitri was in South Africa — standing in the ocean and watching white fog lift off his inflamed skin as the salt water made contact — that something shifted. Not a cure. Not even a treatment. But a signal. The body was responding to something natural in a way it had never responded to anything pharmaceutical. That moment planted a question that he would spend the next several years answering.
If the body could respond like that to something as simple as ocean water — what would happen if you gave it exactly what it needed biologically?
Independent Study Over
The Rockefeller System
Dimitri entered medical school with the intention of understanding the body from the inside. What he found instead was a system designed to produce pharmaceutical prescribers — not healers. Students who asked the wrong questions were discouraged. Papers that challenged the pharmaceutical consensus were unwelcome. During COVID, as medical schools doubled down on vaccine mandates and big pharma protocols, Dimitri was writing papers arguing the opposite — questioning efficacy, examining harm, and proposing alternatives rooted in the body's own biology.
He left. Not because he lost interest in medicine — but because he found that the Rockefeller medical school system was not teaching medicine. It was teaching compliance.
What followed was years of independent research that most formally trained physicians never undertake. He studied nutrition, holistic medicine, Chinese and Ayurvedic practice, Eastern and Western approaches simultaneously — looking for what worked rather than what was approved. He eliminated variables one by one. He eliminated big pharma from his own protocol entirely. His condition improved significantly.
He moved into international business at university — three years of study that gave him the commercial framework to eventually build what he was learning into a platform. But the independent biological research never stopped. It accelerated.
Exosomes.
Everything Changed.
Dimitri's first exosome treatment produced a sensation he had never experienced from any pharmaceutical intervention. Within minutes of the injection, he felt it travel directly to his gut — a washing machine sensation, contractions, biological activity he could physically feel. His energy shifted. His food sensitivities eased. His inflammatory response quieted. This was from a single treatment.
He went deeper. He began reading peer-reviewed studies from every major biologics company operating in the space — Platinum Biologics, Neobiosis, Kimera, Vitro Biopharma, Benev, and others across the United States and Europe. He attended speaker presentations. He spoke with physicians and practitioners. He compared results across manufacturers. He sent products to third-party testing. He tested everything himself.
He was not bound by any single manufacturer or academic affiliation. He had no incentive to favour one source over another. His only criteria was biological quality and clinical outcomes. This independence — unusual in an industry where most practitioners are educated by the companies selling to them — produced conclusions that years of formal study might never have reached.
He concluded that source specificity was everything. Not all exosomes are equivalent. Not all sources carry the same biological information. The tissue of origin determines the signal. And the manufacturing practices determine whether that signal reaches the patient intact.
Second Generation.
First Principles.
Dimitri did not enter biologics without context. His family had been in this industry before him. His stepmother worked in stem cell research at a company whose manufacturing practices pushed the boundaries of what the industry had previously attempted — ultimately contributing to a moment that reshaped the regulatory landscape for stem cell therapies in the United States. She then moved to Neobiosis, a foundational company in the purified amniotic fluid biologics space, before recognising that the future of regenerative biologics lay in the umbilical cord.
This lineage matters. It means Dimitri's entry into biologics was not that of an outsider reading papers. It was the continuation of a family immersed in this field — with access to manufacturer relationships, clinical data, and industry knowledge that most practitioners never have.
But lineage alone does not produce conviction. What Dimitri brought that was genuinely his own was the unbiased perspective of someone with no commercial obligation to any single source — and the personal experience of someone whose body had been the test case. He had lived the difference between pharmaceutical management and biological restoration. He knew what it felt like when the body finally received what it actually needed.
At 21 years old he founded RENOVÓ. Not as a supplement brand. Not as a wellness company. As a regenerative biologics platform built on the principle that the body already knows what to do — and that the only role of medicine is to give it everything it requires to do it.
RENOVÓ
Now
RENOVÓ launched in 2024 with a focused private consulting model — working with a select group of individuals on personalised biological optimisation protocols. From that foundation the platform has expanded into a complete biologics offering: the EXO line for exosome signalling, the Wharton's Jelly line for structural matrix restoration, Conditioned Media for soluble signal environment support, and a comprehensive clinical peptide portfolio for verified partner practices.
Every product in the RENOVÓ portfolio is manufactured to one standard -- the highest biological quality available. Full traceablility from source to delivery. COA on every batch. Zero pathogens. US donors. No compromises.
RENOVÓ works with clinical partners across regenerative medicine, aesthetics, pain management, and longevity — training practitioners on biological selection, protocol design, and the integration of biologics into existing clinical approaches. Dimitri trains the physicians. Not the other way around.
Private consulting remains at the core. For individuals who want a protocol built entirely around their biology — not a demographic, not a condition category, not a pharmaceutical algorithm — Dimitri works with a limited number of clients directly. Every protocol is personal. Every outcome is specific. This is what medicine was always supposed to be.